A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 3

Recruiting

• Conditions: Advanced Non-small Cell Lung Cancer; HER2 Mutation
• Interventions: Drug: BAY2927088; Drug: Pembrolizumab; Drug: Cisplatin; Drug: Carboplatin; Drug: Pemetrexed

• Registration Number: NCT06452277
• Lead Sponsor: Bayer

Brief Summary

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
...

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2024-06-05
• Study First Submitted QC: 2024-06-05
• Study First Posted: 2024-06-11
• Study Start: 2024-08-28
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-14
• Last Update Posted: 2024-11-15
• Primary Completion: 2026-06-02
• Study Completion: 2028-05-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 278

Inclusion Criteria

• Participant must be ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signing the informed consent.
• Documented histologically or cytologically confirmed locally advanced non-squamous NSCLC, not suitable for definitive therapy or metastatic non-squamous NSCLC at screening (small cell or mixed histologies are excluded) (Stage III-IV NSCLC).
• Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified (US sites) or an equally accredited (outside of the US) local laboratory. However, participants may be included at the discretion of the investigator if the laboratory performing the assay is not CLIA or similar certified but the laboratory is locally accredited.
• No prior systemic therapy for locally advanced or metastatic disease. No prior treatment with a HER2 ex20ins-targeted therapy (e.g. poziotinib, trastuzumab deruxtecan). Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the start of screening.
• Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the SmPC/Product Information.

Read More

Exclusion Criteria

• Known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy. Exception: the following cancer types are acceptable within five years if curatively treated or under surveillance:

  • a. in situ cancers of cervix, breast, or skin,
  • b. superficial bladder cancer (Ta, Tis and T1),
  • c. limited-stage prostate cancer,
  • d. basal or squamous cancers of the skin.

• Tumors with targetable alterations with approved available therapy, with the exception of HER2 mutation in the TKD.

• Inability to discontinue treatment with chronic systemic corticosteroids. Participants who require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Replacement therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable, provided that the dose is stable for >4 weeks prior to planned start of study intervention.

• Pre-existing peripheral neuropathy that is Grade ≥2 by CTCAE (v5.0).

• History of severe hypersensitivity reaction to treatment with a monoclonal antibody.

• Prior radiotherapy outside of the brain within 21 days of planned start of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BAY2927088	BAY2927088	Participants will receive BAY2927088 20 mg BID until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Standard of care (SoC)	Pembrolizumab	Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Standard of care (SoC)	Cisplatin	Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Standard of care (SoC)	Carboplatin	Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.
Standard of care (SoC)	Pemetrexed	Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.

Primary Outcome Measures

Name	Time	Method
Progression free survival (PFS) per RECIST 1.1 as assessed by BICR	Up to approximately 2 years	RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR)

Secondary Outcome Measures

Name	Time	Method
Overall survival (OS)	Up to approximately 4 years
Objective response rate (ORR) per RECIST 1.1 as assessed by BICR	Up to approximately 4 years	RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR)
Progression free survival (PFS) per RECIST 1.1 as assessed by the investigator	Up to approximately 4 years	RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1
Objective Response Rate (ORR) as assessed by the investigator	Up to approximately 4 years
Disease control rate (DCR) per RECIST 1.1 as assessed by BICR	Up to approximately 4 years	RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1; BICR = blinded independent central review (BICR)
Disease control rate (DCR) per RECIST 1.1 as assessed by the investigator	Up to approximately 4 years	RECIST 1.1 = Response Evaluation Criteria in Solid Tumors, version 1.1
Duration of response (DOR) as assessed by BICR	Up to approximately 4 years	BICR = blinded independent central review (BICR)
Duration of response (DOR) as assessed by the investigator	Up to approximately 4 years
Adverse events per CTCAE v 5.0 (eg. TEAEs, TESAEs) categorized by severity	Up to approximately 4 years	CTCAE = common terminology criteria for adverse events; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event
Change from baseline in NSCLC-SAQ total score	Up to approximately 4 years	NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire
Change from baseline in NSCLC-SAQ individual domain scores	Up to approximately 4 years	NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire; Domains: cough, pain, dyspnea, fatigue, appetite
Time to deterioration in NSCLC-SAQ total score	Up to approximately 4 years	NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire
Time to deterioration in NSCLC-SAQ individual domain scores	Up to approximately 4 years	NSCLC-SAQ = Non-small cell lung cancer Symptom Assessment Questionnaire; Domains: cough, pain, dyspnea, fatigue, appetite
Time to deterioration in EORTC QLQ-C30 physical functioning domain score	Up to approximately 4 years	EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
Change from baseline in EORTC QLQ-C30 physical functioning domain score	Up to approximately 4 years	EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL: quality of life
Change from baseline in EORTC QLQ-C30 global health status/QoL	Up to approximately 4 years	EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL: quality of life

Trial Locations

Locations (244)

Fujian Cancer Hospital; 🇨🇳 Fuzhou, Fujian, China

Hunan Cancer Hospital; 🇨🇳 Changsha, Hunan, China

Shanghai Chest Hospital, Shanghai Jiaotong University; 🇨🇳 Shanghai, China

Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica; 🇧🇷 Natal, Rio Grande Do Norte, Brazil

Universitaetsklinikum Essen - Innere Klinik (Tumorforschung); 🇩🇪 Essen, North Rhine-Westphalia, Germany

Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

National Cheng Kung University Hospital; 🇨🇳 Tainan, TNN, Taiwan

Aarhus Universitetshospital; 🇩🇰 Aarhus N, Denmark

Odense Universitetshospital - Øjenafdelingen; 🇩🇰 Odense, Denmark

Providence Cancer Institute - Franz Clinic; 🇺🇸 Portland, Oregon, United States

Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati; 🇮🇹 Aviano, Friuli-Venezia Giulia, Italy

Tottori University Hospital; 🇯🇵 Yonago, Tottori, Japan

CHU Grenoble Alpes - Pneumologie; 🇫🇷 La Tronche, France

Institut Gustave Roussy - Département de Médecine Oncologique; 🇫🇷 Villejuif Cedex, France

Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology; 🇨🇦 Toronto, Ontario, Canada

Blacktown Cancer & Haematology Centre; 🇦🇺 Blacktown, New South Wales, Australia

Fudan University - Zhongshan Hospital; 🇨🇳 Shanghai, China

Union Hospi, Tongji Med College, Huazhong Univ. Scien&Tech; 🇨🇳 Wuhan, China

Krajská nemocnice T. Bati - Pneumoonkologická a klinická onkologie; 🇨🇿 Zlin, Zlinsky Kraj, Czechia

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. - GDP Toracica; 🇮🇹 Meldola, Emilia-Romagna, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1; 🇮🇹 Milano, Lombardia, Italy

Istituto Europeo di Oncologia s.r.l - Oncologia Toracica; 🇮🇹 Milano, Lombardia, Italy

Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia; 🇮🇹 Rozzano, Lombardia, Italy

National Hospital Organization Nagoya Medical Center; 🇯🇵 Nagoya, Aichi, Japan

Instituto Nacional de Cancerología; 🇲🇽 México, Distrito Federal, Mexico

Oncare Viaducto Nápoles; 🇲🇽 Cdmx, Mexico

Radboud University Medical Center | Afdeling Interne Geneeskunde; 🇳🇱 Nijmegen, Netherlands

Swietokrzyskie Centrum Onkologii; 🇵🇱 Kielce, Poland

SP ZOZ USK im. WAM UM w Lodzi - Centralny Szpital Weteranow; 🇵🇱 Lodz, Poland

Complejo Hospitalario Universitario A Coruna (CHUAC); 🇪🇸 A Coruna, Spain

Skåne University Hospital; 🇸🇪 Lund, Sweden

Chi-Mei Medical Center, Liouyine; 🇨🇳 Tainan, Taiwan

Taipei Veterans General Hospital; 🇨🇳 Taipei, Taiwan

Ankara Bilkent Sehir Hastanesi; 🇹🇷 Bilkent Çankaya, Turkey

Marmara University Hospital; 🇹🇷 Istanbul, Turkey

Ege Universitesi Tip Fakultesi; 🇹🇷 Izmir, Turkey

Ankara Etlik Sehir Hastanesi; 🇹🇷 Yenimahalle, Turkey

Dnipropetrovsk State Medical Academy - Dnipropetrovsk City Clinical Multi-Type Hospital No.4; 🇺🇦 Dnipropetrovsk, Ukraine

Verum Clinic; 🇺🇦 Kiev, Ukraine

Volyn Regional Oncology Center; 🇺🇦 Lutsk, Ukraine

Belfast City Hospital; 🇬🇧 Belfast, North Ireland, United Kingdom

Nemocnice AGEL Novy Jicin a.s., Oddelení radioterapie a onkologie; 🇨🇿 Novy Jicin, Czechia

University of California Los Angeles (UCLA) - Cancer Care - Santa Monica; 🇺🇸 Santa Monica, California, United States

The U Chicago Medicine Comprehensive Cancer Center; 🇺🇸 Chicago, Illinois, United States

UMass Memorial Medical Center - University Campus; 🇺🇸 Worcester, Massachusetts, United States

Profound Research LLC; 🇺🇸 Farmington Hills, Michigan, United States

Concord Repatriation General Hospital - Medical Oncology Clinical Trials Unit; 🇦🇺 Concord, New South Wales, Australia

Calvary Mater Hospital Newcastle; 🇦🇺 Waratah, New South Wales, Australia

University of the Sunshine Coast; 🇦🇺 Buderim, Australia

The Canberra Hospital (TCH) - Canberra Region Cancer Centre (CRCC); 🇦🇺 Garran, Australia

Austin Hospital - Olivia Newton John Cancer Research Institute; 🇦🇺 Heidelberg, Australia

Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III; 🇦🇹 Salzburg, Austria

Uniklinikum Salzburg, Universitätsklinik für Pneumologie/ Lungenheilkunde; 🇦🇹 Salzburg, Austria

Medizinische Universität Wien Universitätsklinik f. Innere Medizin I Klinische Abteilung für Onkologie; 🇦🇹 Wien, Austria

Klinik Floridsdorf, Pneumo-onkologische Ambulanz und Tagesklinik; 🇦🇹 Wien, Austria

Universiteit Ziekenhuis Antwerpen | Thoraxheelkunde Afdeling; 🇧🇪 Edegem, Belgium

UZ Leuven Gasthuisberg; 🇧🇪 Leuven, Belgium

AZ Delta | Clinical Trial Center - Pneumology; 🇧🇪 Roeselare, Belgium

Rede DoR Recife - PE; 🇧🇷 Recife, Pernambuco, Brazil

Fundacao Pio XII - Hospital de Cancer de Barretos; 🇧🇷 Barretos, Sao Paulo, Brazil

NAIC - Instituto do Cancer; 🇧🇷 Bauru, Brazil

Clinica de Oncologia Reichow; 🇧🇷 Blumenau, Brazil

Hospital Sirio-Libanes (HSL) - Centro de Oncologia - Brasilia; 🇧🇷 Brasilia, Brazil

Pronutrir Fortaleza - CE; 🇧🇷 Fortaleza, Brazil

A Beneficencia Portuguesa de Sao Paulo - Hospital BP Mirante; 🇧🇷 Sao Paulo, Brazil

Hospital Sirio Libanes; 🇧🇷 Sao Paulo, Brazil

Centro Paulista de Oncologia (CPO) - Sao Paulo - Faria Lima; 🇧🇷 Sao Paulo, Brazil

MHAT "Heart and brain" Pleven; 🇧🇬 Pleven, Bulgaria

Complex Oncology Center - Plovdiv EOOD; 🇧🇬 Plovdiv, Bulgaria

Multiprofile Hospital for Active Treatment "Sveta Sofia"; 🇧🇬 Sofia, Bulgaria

MHAT Serdika; 🇧🇬 Sofia, Bulgaria

Specialized Hospital for Active Treatment of Oncology; 🇧🇬 Sofia, Bulgaria

Jewish General Hospital - Department of Pulmonary Oncology; 🇨🇦 Montreal, Quebec, Canada

BC Cancer - The Vancouver Centre; 🇨🇦 Vancouver, Canada

Beijing Hospital; 🇨🇳 Beijing, China

NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School; 🇨🇳 Nanjing, Jiangsu, China

Jilin Cancer Hospital; 🇨🇳 Changchun, Jilin, China

West China Hospital Sichuan University; 🇨🇳 Chengdu, Sichuan, China

Cancer Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, China

Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China

Beijing Cancer Hospital; 🇨🇳 Beijing, China

Beijing chest hospital, Capital Medical University; 🇨🇳 Beijing, China

University of Electronic Science & Technology of China - Sichuan Cancer Hospital & Institute (Sichuan Provincial Tumor Hospital); 🇨🇳 Chengdu, China

Guangzhou Medical University - The First Affiliated Hospital; 🇨🇳 Guangzhou, China

Harbin Medical University Cancer Hospital; 🇨🇳 Harbin, China

Zhejiang Cancer Hospital; 🇨🇳 Hangzhou, China

LinYi Cancer Hospital (Linyi Tumor Hospital); 🇨🇳 Linyi, China

Shandong University - Shandong Cancer Hospital; 🇨🇳 Jinan, China

Guangxi Medical University (GXMU) - Affiliated Tumor Hospital; 🇨🇳 Nanning, China

Hubei Cancer Hospital; 🇨🇳 Wuhan, China

Zhejiang University School of Medicine - Taizhou Hospital of Zhejiang Province; 🇨🇳 Taizhou, China

Xiamen University - The First Affiliated Hospital; 🇨🇳 Xiamen, China

Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP); 🇨🇿 Brno, Czechia

Klinika plicnich nemoci a tuberkulozy - Fakultni nemocnice Olomouc; 🇨🇿 Olomouc, Czechia

Vitkovicka nemocnice a.s.; 🇨🇿 Ostrava, Czechia

Aalborg University Hospital; 🇩🇰 Aalborg, Denmark

Docrates Cancer Center; 🇫🇮 Helsinki, Finland

Regionshospitalet Gødstrup - Medicinsk afdeling; 🇩🇰 Herning, Denmark

Rigshospitalet - Hjertesygdomme; 🇩🇰 København Ø, Denmark

Institut Bergonié - Unicancer Nouvelle Aquitaine; 🇫🇷 Bordeaux Cedex, France

Turun yliopistollinen keskussairaala; 🇫🇮 Turku, Finland

Centre Hospitalier Intercommunal Créteil - Service de pneumologie; 🇫🇷 Créteil, France

Institut de Cancérologie et d'Imagerie; 🇫🇷 Brest, France

Institut Coeur Poumon - CHRU Lille - Pôle Cardio-vasculaire et pulmonaire; 🇫🇷 Lille, France

CHU Limoges - Unité oncologie thoracique; 🇫🇷 Limoges, France

Hôpital Arnaud de Villeneuve - Montpellier; 🇫🇷 Montpellier, France

Institut Curie - Ulm - Paris; 🇫🇷 PARIS cedex 5, France

Hôpital Emile Muller - Mulhouse; 🇫🇷 Mulhouse, France

CHU de Rouen - Pneumologie; 🇫🇷 Rouen, France

Hôpital Cochin - Cancérologie; 🇫🇷 Paris, France

Hôpital Lyon Sud - HCL - Service de pneumologie aiguë spécialisée et cancérologie thoracique; 🇫🇷 Pierre Bénite, France

Hôpital Foch - Oncologie digestive et thoracique; 🇫🇷 Suresnes, France

Institut de Cancérologie de l'Ouest - Saint Herblain; 🇫🇷 Saint-Herblain, France

Universitaetsklinikum Giessen und Marburg - Medizinische Klinik IV Organonkologie; 🇩🇪 Gießen, Hessen, Germany

Lungenklinik Hemer, Thorakale Onkologie und onkologische Palliativmedizin; 🇩🇪 Hemer, Germany

University of Athens Medical School-Sotiria General Hospital; 🇬🇷 Athens, Greece

Robert Bosch Krankenhaus - Haematologie, Onkologie und Palliativmedizin; 🇩🇪 Stuttgart, Germany

University of Athens Medical School- Alexandra General Hospital of Athens; 🇬🇷 Athens, Greece

Metropolitan Hospital- 4th Oncology Clinic; 🇬🇷 Athens, Greece

University General Hospital of Athens "ATTIKON"; 🇬🇷 Chaidari, Greece

University General Hospital ATTIKON, Department of Internal Medicine IV; 🇬🇷 Chaidari, Greece

University General Hospital of Larissa; 🇬🇷 Larissa, Greece

Bioclinic Thessaloniki; 🇬🇷 Thessaloniki, Greece

PAPANIKOLAOU General Hospital of Thessaloniki; 🇬🇷 Thessaloniki, Greece

Queen Mary Hospital; 🇭🇰 Hong Kong, Hong Kong

Budapesti Uzsoki Utcai Korhaz; 🇭🇺 Budapest, Hungary

Prince of Wales Hospital; 🇭🇰 Shatin, Hong Kong

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOSD Oncologia Toraco-Polmonare; 🇮🇹 Roma, Lazio, Italy

Soroka Medical Center- Legacy Heritage Cancer Center; 🇮🇱 Be'er Sheva, Israel

Shaare Zedek Medical Center (SZMC); 🇮🇱 Jerusalem, Israel

Tel-Aviv Sourasky Medical Center; 🇮🇱 Tel Aviv, Israel

I.F.O. Istituti Fisioterapici Ospitalieri_Ospedale Regina Elena -- Oncologia Medica 2; 🇮🇹 Roma, Lazio, Italy

Centro Ricerche Cliniche Di Verona S.r.l. - Oncologia; 🇮🇹 Verona, Italy

Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica; 🇮🇹 Orbassano, Piemonte, Italy

National Cancer Center Hospital East; 🇯🇵 Kashiwa, Chiba, Japan

Istituto Oncologico Veneto - UOC Oncologia 2; 🇮🇹 Padova, Veneto, Italy

National Hospital Organization Himeji Medical Center; 🇯🇵 Himeji, Hyogo, Japan

Kitasato University Hospital; 🇯🇵 Sagamihara, Kanagawa, Japan

Saitama Cancer Center; 🇯🇵 Kitaadachi-gun, Saitama, Japan

Sendai Kousei Hospital; 🇯🇵 Sendai, Miyagi, Japan

Kansai Medical University Hospital; 🇯🇵 Hirakata, Osaka, Japan

Nippon Medical School - Nippon Medical School Hospital - Cancer Center; 🇯🇵 Bunkyo-ku, Tokyo, Japan

Kindai University Hospital; 🇯🇵 Osakasayama, Osaka, Japan

National Hospital Organization-Yamaguchi-Ube Medical Center (Sanyo Hospital); 🇯🇵 Ube, Japan

Osaka International Cancer Institute; 🇯🇵 Osaka, Japan

Chungbuk National University Hospital; 🇰🇷 Cheongju-si, Chungcheongbugdo, Korea, Republic of

Gyeongsang National University Hospital; 🇰🇷 Jinju-si, Gyeongsangnam-do, Korea, Republic of

Pusan National University Yangsan Hospital; 🇰🇷 Yangsan-si, Gyeongsangnamdo, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Chonnam National University Hwasun Hospital; 🇰🇷 Hwasun Gun, Korea, Republic of

Severance Hospital, Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of

Sunway Medical Centre Penang; 🇲🇾 Perai, Malaysia

Sunway Medical Centre; 🇲🇾 Subang Jaya, Selangor, Malaysia

University Malaya Medical Centre; 🇲🇾 Kuala Lumpur, Malaysia

Oncología Integral Satélite; 🇲🇽 Naucalpan, Mexico

Beacon Hospital; 🇲🇾 Petaling Jaya, Selangor, Malaysia

Hospital Universitrio Dr. José Eleuterio González. Servicio de Oincología; 🇲🇽 Nuevo León, Mexico

Uniwersytecki Szpital Kliniczny w Bialymstoku; 🇵🇱 Bialystok, Poland

Nederlands Kanker Instituut; 🇳🇱 Amsterdam, Netherlands

ONCARE Treatment Center; 🇲🇽 San Pedro Garza García, Mexico

Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku; 🇵🇱 Otwock, Poland

Fundacao Champalimaud | Centro Clinico Champalimaud - Unidade Investigacao Clinica; 🇵🇹 Lisboa, Portugal

Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii; 🇵🇱 Wroclaw, Poland

IPO Porto; 🇵🇹 Porto, Portugal

CHULN - Hospital Pulido Valente; 🇵🇹 Lisboa, Portugal

ULSM - Hospital Pedro Hispano; 🇵🇹 Matosinhos, Portugal

Radiotherapy Center Cluj SRL; 🇷🇴 Flore?ti, Comuna Floresti, Romania

Institutul Oncologic Prof. Dr. Alexandru Trestioreanu (IOB); Oncologie Medicala II; 🇷🇴 Bucuresti, Romania

Sc Oncolab Srl; 🇷🇴 Craiova, Romania

Centrul de Oncologie Sfantul Nectarie; 🇷🇴 Craiova, Romania

Raffles Cancer Centre; 🇸🇬 Singapore, Singapore

OncoCare Cancer Centre | Gleneagles Medical Centre; 🇸🇬 Singapore, Singapore

Tan Tock Seng Hospital; 🇸🇬 Singapore, Singapore

Curie Oncology | Farrer; 🇸🇬 Singapore, Singapore

POKO Poprad s.r.o.; 🇸🇰 Poprad, Slovakia

Fakultna nemocnica Trnava; 🇸🇰 Trnava, Slovakia

Hospital Quiron Dexeus; 🇪🇸 Barcelona, Spain

Hospital Universitario Clinica Puerta de Hierro; 🇪🇸 Majadahonda, Madrid, Spain

Institut Catala d'Oncologia (ICO) - Hospital Universitari Germans Trias i Pujol (HUGTP) Location; 🇪🇸 Badalona, Spain

Complejo Hospitalario de Navarra; 🇪🇸 Pamplona, Spain

Hospital General Universitario Gregorio Maranon | Oncologia; 🇪🇸 Madrid, Spain

Fundacion Jimenez Diaz (Clinica de la Concepcion); 🇪🇸 Madrid, Spain

Ciutat Sanitaria i Universitaria de la Vall d'Hebron; 🇪🇸 Barcelona, Spain

Hospital Clinic de Barcelona (Hospital Clinic i Provincial); 🇪🇸 Barcelona, Spain

Fundacion Instituto Valenciano de Oncologia (IVO; 🇪🇸 Valencia, Spain

Hospital Universitari i Politecnic La Fe | Oncologia; 🇪🇸 Valencia, Spain

Norrland University Hospital - Cancercentrum; 🇸🇪 Umeå, Sweden

Chung Shan Medical University Hospital; 🇨🇳 Taichung, Taiwan

Taichung Veterans General Hospital; 🇨🇳 Taichung, Taiwan

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan

National Taiwan University Hospital (NTUH) - Cancer Research Center; 🇨🇳 Taipei, Taiwan

Istanbul Medeniyet Üniversitesi Göztepe Süleyman Yalçin Sehir Hastanesi; 🇹🇷 Kadikoy, Turkey

I.A.Ü. VM Medical Park Florya Hastanesi; 🇹🇷 Kucukcekmece, Turkey

Sakarya Universitesi Egitim ve Arastirma Hastanesi; 🇹🇷 Sakarya, Turkey

Adana Sehir Egitim ve Arastirma Hastanesi; 🇹🇷 Yüregir, Turkey

P.L. Shupyk National Medical Academy of Post-Graduate Education - Kyiv city clinical Oncology Center; 🇺🇦 Kiev, Ukraine

St. Luke's Hospital (Medical and Diagnostic Center "Acinus''); 🇺🇦 Kirovograd, Ukraine

Limited Liability Company "MedOffice Group Medical Center"; 🇺🇦 Kyiv, Ukraine

Yuri Semenyuk Rivne Regional Clinical Hospital; 🇺🇦 Rivne, Ukraine

Uzhhorod Central City Clinical Hospital; 🇺🇦 Uzhgorod, Ukraine

Royal Surrey County Hospital; 🇬🇧 Guildford, Surrey, United Kingdom

Hospital de Base | Integrated Research Center; 🇧🇷 São José do Rio Preto, Sao Paulo, Brazil

Kliniken der Stadt Koeln gGmbH - Krankenhaus Koeln Merheim - Lungenklinik; 🇩🇪 Köln, Nordrhein-Westfalen, Germany

Klinikum Nürnberg; 🇩🇪 Nürnberg, Germany

National Hospital Organization Kyushu Medical Center; 🇯🇵 Fukuoka, Japan

Assuta Ashdod; 🇮🇱 Ashdod, Israel

Kobe University Hospital; 🇯🇵 Kobe, Hyogo, Japan

Niigata Cancer Center Hospital; 🇯🇵 Niigata, Japan

AORN San Giuseppe Moscati Avellino - U.O.C. Oncologia Medica; 🇮🇹 Avellino, Campania, Italy

Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - UOC Oncologia Medica; 🇮🇹 Bologna, Emilia-Romagna, Italy

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Hokkaido University Hospital; 🇯🇵 Sapporo, Hokkaido, Japan

MHAT Park Hospital EOOD; 🇧🇬 Plovdiv, Bulgaria

MHAT Sofiamed; 🇧🇬 Sofia, Bulgaria

MHAT Sveta Marina EAD; 🇧🇬 Varna, Bulgaria

Komarom-Esztergom Varmegyei Szent Borbala Korhaz; 🇭🇺 Tatabanya, Hungary

MHAT Uni Hospital; 🇧🇬 Panagyurishte, Pazardzhik, Bulgaria

Torbay Hospital; 🇬🇧 Torbay, Devon, United Kingdom

Wielkopolskie Centrum Pulmonologii i Torakochirurgii; 🇵🇱 Poznan, Poland

Spitalul Clinic Coltea; 🇷🇴 Bucuresti, Romania

Kaohsiung Medical University Chung-Ho Memorial Hospital; 🇨🇳 Kaohsiung, Taiwan

Kantonsspital Baden; 🇨🇭 Baden, Aargau, Switzerland

The People's Liberation Army General Hospital (Beijing 301 Hospital); 🇨🇳 Beijing, China

Hoag Memorial Hospital - Center for Research & Education; 🇺🇸 Newport Beach, California, United States

University of Maryland; 🇺🇸 Baltimore, Maryland, United States

The Oncology Institute of Hope and Innovation; 🇺🇸 Whittier, California, United States

Fundación Cenit para la Investigación en Neurociencias; 🇦🇷 Caba, Ciudad Auton. De Buenos Aires, Argentina

Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC); 🇦🇷 Buenos Aires, Argentina

Centro Médico Privado CEMAIC; 🇦🇷 Córdoba, Argentina

Instituto Argentino de Diagnostico y Tratamiento (IADT); 🇦🇷 TBC, Argentina

Centro de Investigaciones Clínicas, Clínica Viedma; 🇦🇷 Viedma, Argentina

Hospital Italiano de Buenos Aires; 🇦🇷 Buenos Aires, Argentina

UC San Diego Health - Moores Cancer Center; 🇺🇸 San Diego, California, United States

Memorial Healthcare System; 🇺🇸 Hollywood, Florida, United States

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Antwerp University Hospital | Oncology Department; 🇧🇪 Antwerpen, Belgium

Centro de Pesquisa da Clínica de Oncologia Reichow; 🇧🇷 Blumenau, Santa Catarina, Brazil

Nanjing Medical University (NMU) - Jiangsu Province Hospital (First Affiliated Hospital); 🇨🇳 Nanjing, China

Hong Kong United Oncology Centre; 🇭🇰 Kowloon, Hong Kong

Queen Elizabeth Hospital Hong Kong; 🇭🇰 Hong Kong, Hong Kong

Northwell Health Cancer Institute - R.J. Zuckerberg Cancer Center (Monter Cancer Center) - Center for Advanced Medicine Location; 🇺🇸 New Hyde Park, New York, United States

University of California San Francisco (UCSF) - Thoracic Surgery and Oncology Clinic; 🇺🇸 San Francisco, California, United States

University of Cincinnati Medical Center; 🇺🇸 Cincinnati, Ohio, United States

UT Southwestern; 🇺🇸 Dallas, Texas, United States